Psoriatic Arthritis Psa clinical trials

Explore recruiting psoriatic arthritis psa clinical trials.

Recruiting psoriatic arthritis psa studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psoriatic Arthritis Psa trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

Spain, Germany, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis.

Czechia, Slovakia, Croatia, Latvia, Hungary, Lithuania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, RISANKIZUMABCONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT STUDY PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS

Germany, Poland, Bulgaria, Spain, Hungary, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3B exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis.

Poland, Germany

Phase III and phase IV (Integrated) EU CTIS Study details

Psoriatic Arthritis Psa trials by city

Psoriatic Arthritis Psa in Toronto Psoriatic Arthritis Psa in Vancouver Psoriatic Arthritis Psa in Montreal Psoriatic Arthritis Psa in Calgary Psoriatic Arthritis Psa in Edmonton Psoriatic Arthritis Psa in Ottawa Psoriatic Arthritis Psa in Winnipeg Psoriatic Arthritis Psa in Quebec City Psoriatic Arthritis Psa in Hamilton Psoriatic Arthritis Psa in Kitchener Psoriatic Arthritis Psa in London Psoriatic Arthritis Psa in Halifax Psoriatic Arthritis Psa in New York Psoriatic Arthritis Psa in Los Angeles Psoriatic Arthritis Psa in Chicago Psoriatic Arthritis Psa in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease